Alta Partners’ most common sectors for investment are life science (84%) and medical products (12%). The Firm’s most common investment types include venture (80%) and pipe (9%). In total, Alta Partners has invested in 8 US states and 7 different countries. Its largest (disclosed) acquisition occurred in 2012 when it acquired Bioventus for $118M.
In the last 3 years, Alta Partners has exited 3 companies. The Firm’s most common exit type is trade sale (63%). Alta Partners’ largest (disclosed) exit occurred in 2019 when it sold Ellie Mae for $3.7B.
Join Mergr to view Alta Partners’ full profile and discover more large private equity firms just like it.
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
Join Mergr to view the latest updates and news from San Francisco-based Alta Partners.
We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.
Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.
Try us for 1 week free today!
No obligation. Cancel anytime.